<DOC>
	<DOCNO>NCT02596984</DOCNO>
	<brief_summary>Although pharmacokinetics Caspofungin study healthy subject patient , study perform critically-ill patient . In patient several factor , include sepsis , shock , increased distribution volume , hepatic dysfunction hypoalbuminemia may result dramatic change antibiotic concentration pharmacokinetics . Caspofungin pharmacokinetic data scarce result mainly case series animal study . Thus , study perform far show Caspofungin trough concentration either decrease , similar usual value non-critically ill patient increase . One study suggest body weight hypoalbuminemia may main factor associate Caspofungin pharmacokinetic variability . Pharmacokinetic parameter caspofungin pig hypovolemic shock suggest peripheral volume distribution caspofungin intercompartmental clearance higher healthy animal . These result however preliminary extrapolate suggest clinical study human need . The primary objective study assess Caspofungin trough concentration pharmacokinetics critically-ill patient require vasopressor .</brief_summary>
	<brief_title>Evaluation Pharmacokinetics Caspofungin ICU Patients</brief_title>
	<detailed_description />
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Adult patient ( age &gt; 18 y.o ) Either preemptive , empirical curative prescription Caspofungin one ICUs ' attend physician Requiring vasopressor Admission one participate ICUs . Pregnancy Lack affiliation National Medical Insurance Previous inclusion study Inclusion concomitant study may interact current study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Intensive Care Unit</keyword>
	<keyword>Shock</keyword>
	<keyword>Antifungal agent</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sepsis</keyword>
</DOC>